Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

CLRB

Cellectar Biosciences (CLRB)

Cellectar Biosciences Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CLRB
DateTimeSourceHeadlineSymbolCompany
05/24/20243:46PMEdgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:CLRBCellectar Biosciences Inc
05/16/20245:05AMEdgar (US Regulatory)Form DEFR14A - Revised definitive proxy soliciting materialsNASDAQ:CLRBCellectar Biosciences Inc
05/14/20245:45AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CLRBCellectar Biosciences Inc
05/14/20245:40AMGlobeNewswire Inc.Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate UpdateNASDAQ:CLRBCellectar Biosciences Inc
05/14/20245:32AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CLRBCellectar Biosciences Inc
05/08/20245:40AMGlobeNewswire Inc.Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals DayNASDAQ:CLRBCellectar Biosciences Inc
05/07/20245:40AMGlobeNewswire Inc.Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, May 14, 2024NASDAQ:CLRBCellectar Biosciences Inc
03/27/20245:40AMGlobeNewswire Inc.Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate UpdateNASDAQ:CLRBCellectar Biosciences Inc
03/20/20245:40AMGlobeNewswire Inc.Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024NASDAQ:CLRBCellectar Biosciences Inc
03/14/20247:52AMGlobeNewswire Inc.Cellectar Biosciences to Present at the 36th Annual Roth ConferenceNASDAQ:CLRBCellectar Biosciences Inc
03/04/20245:40AMGlobeNewswire Inc.Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck CancerNASDAQ:CLRBCellectar Biosciences Inc
02/14/20247:31PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CLRBCellectar Biosciences Inc
02/14/20243:29PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CLRBCellectar Biosciences Inc
02/07/20245:40AMGlobeNewswire Inc.Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:CLRBCellectar Biosciences Inc
02/02/20245:03AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CLRBCellectar Biosciences Inc
01/31/20247:00AMEdgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:CLRBCellectar Biosciences Inc
01/30/20245:40AMGlobeNewswire Inc.Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical StudyNASDAQ:CLRBCellectar Biosciences Inc
01/25/20243:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CLRBCellectar Biosciences Inc
01/25/20245:40AMGlobeNewswire Inc.Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 MillionNASDAQ:CLRBCellectar Biosciences Inc
01/22/20245:40AMGlobeNewswire Inc.Cellectar Biosciences Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom’s Macroglobulinemia PatientNASDAQ:CLRBCellectar Biosciences Inc
01/16/20245:40AMGlobeNewswire Inc.Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT) for Solid Tumors and Releases Promising Preclinical DataNASDAQ:CLRBCellectar Biosciences Inc
01/12/20245:44AMGlobeNewswire Inc.Cellectar Biosciences to Host Conference Call with Texas Oncology Hematologist M. Yair Levy, M.D. on January 19, 2024 to Discuss Iopofosine I 131 Pivotal Topline ResultsNASDAQ:CLRBCellectar Biosciences Inc
01/11/20245:40AMGlobeNewswire Inc.Cellectar Biosciences Partners with MiBA, a Data Subsidiary of American Oncology Network, to Advance the Treatment of Waldenstrom's Macroglobulinemia in the Community SettingNASDAQ:CLRBCellectar Biosciences Inc
01/09/20245:02AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CLRBCellectar Biosciences Inc
01/08/20245:30AMGlobeNewswire Inc.Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom’s MacroglobulinemiaNASDAQ:CLRBCellectar Biosciences Inc
01/03/20247:30AMGlobeNewswire Inc.Cellectar Biosciences to Announce Top-line Data from WM Pivotal Trial on January 8, 2024NASDAQ:CLRBCellectar Biosciences Inc
12/19/20237:30AMGlobeNewswire Inc.Cellectar Biosciences Expands Iopofosine I 131 Collaboration with Wisconsin Alumni Research FoundationNASDAQ:CLRBCellectar Biosciences Inc
12/12/20237:09PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CLRBCellectar Biosciences Inc
12/12/20237:07PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CLRBCellectar Biosciences Inc
12/12/20237:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CLRBCellectar Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:CLRB

Your Recent History

Delayed Upgrade Clock